Nanomedicine is the application of nanotechnology to achieve innovation in healthcare. It uses the properties developed by a material at its nanometric scale 10-9 m which often differ in terms of physics, chemistry or biology from the same material at a bigger scale.

Moreover, the nanometric size is also the scale of many biological mechanisms in the human body allowing nanoparticles and nanomaterials to potentially cross natural barriers to access new sites of delivery and to interact with DNA or small proteins at different levels, in blood or within organs, tissues or cells.

As a major pan-European industry-oriented initiative, the ETPN aims at strengthening Europe’s capabilities and competitiveness in the area of nanomedicine innovation. Since 2005 the ETPN published a number of strategic documents outlining the needs and roadmaps for nanomedicine research in Europe.

We have contributed to set up numerous European funded projects providing a first impression of the conditions for a suitable social and economic environment and the structural requirements for an efficient translation of R&D results into innovative nanomedicine.

Complementary to its strategic inputs as an ETP to shape and support public funding on the most promising areas of Nanomedicine, the ETPN has designed in 2014 unique technical infrastructures regrouped in a central instrument: the Nanomedicine Translation HUB.

These free of charge services support and accelerate the development of the best Nanomedicine projects from innovative design to clinical development.

• Meet new partners and end-users
• Share your success stories
• Benefit from unique advantages
• Shape the future of Nanomedicine in europe
• Promote and educate

The NanoMed Map provides thorough insights into the nanomedicine community by showing all the actors of the ecosystem in Europe and beyond. It was initiated by NanoMed 2020, CSA project under FP7_Health.